PPD, Inc. (Nasdaq: PPDI) today announced it will present on key industry topics at the 2008 IIR Partnerships with CROs conference held April 14-16 in Las Vegas. IIR has selected several PPD industry experts to speak on topics including financial strategies and CRO partnerships, single-sourcing global central labs and global feasibility assessments.
PPD leaders will moderate, present or participate on the following panels:
Monday, April 14
- Financial Strategies to Enhance Partnerships—1:30-4:30 p.m. PST
Pharmaceutical and CRO panel participants will explore factors driving the industry to adopt different financial models, benefits and challenges of different models and reasons for selecting a particular financial model. Randy Marchbanks, vice president, business development, Americas, will moderate the panel, which includes William Sharbaugh, PPD’s chief operating officer.
Tuesday, April 15
- Benefits of Global Feasibility Assessments—5:00-5:45 p.m. PST
This session will explore the benefits of conducting feasibility assessments early in the development process, as well as available tools and factors to consider for a global assessment. J. Kyle Bryan, M.D., executive medical director, global drug development is participating in the session.
- Case Study: Explore Both Sides of the CRO/Pharmaceutical Partnership to Build a Strong Unified Project Team—5:00-5:45 p.m. PST
Panelists will discuss the value of CRO/pharmaceutical industry experience when using a proactive approach for conducting a trial and the essential steps for building a strong, unified project team. The session includes Michael Brooks, senior director, clinical operations.
Wednesday, April 16
- Single-Sourcing Central Lab and CRO services: Benefits and Opportunities—2:15-3:00 p.m. PST
This session presents provider and client perspectives on selection of a central lab including project management, timing and resource optimization. The panel includes Agostino Fede, Ph.D., senior vice president, global central lab services.
- How to Be an Ally and a Competitor at the Same Time—2:15-3:00 p.m. PST
Attendees will learn lessons, implications and risk factors for strategic alliances between CROs and clients as well as cultures conducive to these multi-level relationships. Kerry Toone, general manager, key accounts will participate in this panel.
For more information about presentations and panels, visit PPD at booth 611 throughout the conference.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the value of the information presented during these presentations, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
PPD, Inc.
Media:
Sue Ann Pentecost, 919-456-5890
sueann.pentecost@rtp.ppdi.com
or
Analysts/Investors:
Craig
Eastwood, 910-558-7585
craig.eastwood@wilm.ppdi.com